Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-817MA in MCI due to AD or mild AD
NCT04191486Phase 2Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Dec 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of edonerpic in Alzheimer's disease (AD), sponsored by FUJIFILM Toyama Chemical. Primary endpoint: Change in Cerebrospinal Fluid Phosphorylated Tau 181 at 78 weeks. Started Dec 2019; status: completed.
02
Drugs
edonerpic
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04191486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191486.